Samsung Biologics to produce clinical supply as UCB advances Ph I immunotherapy study

By Maggie Lynch

- Last updated on GMT

(Image: Getty/ Pattanaphong Khuankaew)
(Image: Getty/ Pattanaphong Khuankaew)

Related tags Samsung biologics Clinical supply Immunotherapy Manufacturing phase I

Samsung Biologics and UCB agree to an additional drug substance manufacturing deal to produce an anti-tau candidate currently in Phase I clinical trials to treat progressive supranuclear palsy.

The drug substance from UCB, UCB0107, is an anti-tau candidate currently in Phase I clinical studies. Per the agreement, Samsung Biologics will produce the drug candidate while the clinical study is ongoing.

The neurology lead at UCB, Jim Baxter, told us that this partnership was an important component for the development process of the drug candidate as it ensures the consistent supply needed for the program.

UCB, a Belgium-based biopharmaceutical focused on neurology and immunology, developed the drug candidate and has previously worked​ with Samsung Biologics to develop and manufacture an investigational drug in 2018.

“In progressing our UCB0107 development program, our goal is to develop a novel medicine which delays progression of progressive supranuclear palsy and increases the time where patients can experience the life they want to live,”​ Baxter told us.

The two companies have signed two sub-agreements as well. The agreements see Samsung Biologics manufacturing UCB’s products currently in clinical development, including therapies for the treatment of myasthenia gravis, psoriasis, and psoriatic arthritis.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars